Highlights of the development in personalized treatment of patients with diffuse large B-cell lymphoma:reports in the 54 ASH annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 71-73, 2013.
Article
em Zh
| WPRIM
| ID: wpr-466490
Biblioteca responsável:
WPRO
ABSTRACT
The outcome of diffuse.Large B-cell lymphoma (DLBCL) has been improved in the last decades and will be raised further with the development of novel agents in the future.Personalized treatment for DLBCL is based on its molecular heterogeneity.Except for concurrent translocation of myc and bcl-2,neither clinical nor biological factor is sufficiently available to be used to guide the deviation of R-CHOP therapy in DLBCL.Gene expression profiling and whole genomic analytic techniques are expected to be important approaches at present to determine personalized treatment for DLBCL.The advance in the field being reported by Laurie H.Sehn from University of British Columbia in the 54 ASH meeting was summarized in the paper.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2013
Tipo de documento:
Article